Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV difelikefalin safety study in adolescents on hemodialysis with moderate-to-severe pruritus
2023-509909-74-00Phase 2Authorised
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
- Start
- Aug 2025
- Modality
- Peptides
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of difelikefalin in chronic kidney disease (CKD), sponsored by Vifor Fresenius Medical Care Renal Pharma. Primary endpoint: Incidence of adverse events. Planned start Aug 2025; status: authorised.
02
Drugs
difelikefalin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-509909-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509909-74-00.